Compare Palo Alto Networks Inc (PANW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Palo Alto Networks Inc trades at $372.05 (market cap $324.77B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Palo Alto Networks Inc is far larger — about 66.6× Travere Therapeutics Inc. Common Stock's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PANW | TVTX | |
|---|---|---|
Market Cap | $324.77B | $4.88B |
Volume | 3,473,783 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $419.91 | $67.52 |
52-Week Low | $141.67 | $26.79 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $324.20B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $375.04, down 7.13% over the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive sentiment from 64 buy ratings. Recent earnings beats and robust revenue growth to $9.22B in 2025 highlight fundamental strength, though valuation ratios remain elevated with a P/E of 992.58. The company's AI-driven security platform and continuous defense services are key growth drivers, positioning it well in the cybersecurity sector.
Outlook: PANW's AI integration and platformization strategy support long-term growth, with a consensus price target of $400.05 offering ~6.7% upside. Risks include premium valuation, rising costs, and competitive pressures. Investors should weigh strong fundamentals against high multiples.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
